Pastor R, Habersetzer F, Fafi-Kremer S, Doffoël M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol 2009; 15(6): 753-755 [PMID: 19222103 DOI: 10.3748/wjg.15.753]
Corresponding Author of This Article
Dr. Evelyne Schvoerer, Institut de Virologie, 3 Rue Koeberlé, 67000 Strasbourg, France. evelyne.schvoerer@chru-strasbourg.fr
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 14, 2009; 15(6): 753-755 Published online Feb 14, 2009. doi: 10.3748/wjg.15.753
Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients
Rebecca Pastor, François Habersetzer, Samira Fafi-Kremer, Michel Doffoël, Thomas F Baumert, Jean-Pierre Gut, Françoise Stoll-Keller, Evelyne Schvoerer
Rebecca Pastor, Samira Fafi-Kremer, Jean-Pierre Gut, Françoise Stoll-Keller, Evelyne Schvoerer, Laboratoire de Virologie, CHRU de Strasbourg, 3 Rue Koeberlé, 67000 Strasbourg, France
Samira Fafi-Kremer, Thomas F Baumert, Jean-Pierre Gut, Françoise Stoll-Keller, Evelyne Schvoerer, Inserm U 748, Strasbourg, 3 Rue Koeberlé, 67000 Strasbourg, France
François Habersetzer, Michel Doffoël, Thomas F Baumert, Service d’Hépato-gastroentérologie, Nouvel Hôpital Civil, 1 Place de l’Hôpital, 67091 Strasbourg, France
Samira Fafi-Kremer, Thomas F Baumert, Jean-Pierre Gut, Françoise Stoll-Keller, Evelyne Schvoerer, Université Louis Pasteur, Faculté de Médecine, 4 Rue Kirschleger, 67084 Strasbourg, France
Author contributions: Pastor R performed the experiments, analyzed the data and wrote the manuscript; Habersetzer F, Doffoël M and Baumert TF contributed to the manuscript writing as experts in Hepato-gastroenterology and in viral hepatitis field; Fafi-Kremer S, Gut JP and Stoll-Keller F contributed to the virological analyses; Schvoerer E conducted the study and wrote the manuscript.
Correspondence to: Dr. Evelyne Schvoerer, Institut de Virologie, 3 Rue Koeberlé, 67000 Strasbourg, France. evelyne.schvoerer@chru-strasbourg.fr
Telephone: +33-390243696
Fax: +33-390243750
Received: September 26, 2008 Revised: December 17, 2008 Accepted: December 24, 2008 Published online: February 14, 2009
Abstract
Anti-hepatitis B virus (HBV) therapy leads to the emergence of mutant viral strains during the treatment of chronic hepatitis B with nucleos(t)ides analogues. The existence of HBV variants with primary antiviral resistance may be important for treatment choice. We studied two patients with chronic HBV infection by sequencing the HBV polymerase gene. They had adefovir- and tenofovir-related mutations in the viral polymerase, although they had never been treated. These mutations were rtV214A/rtN238T in one patient and rtA194T in the other. Thus, mutations in untreated patients deserve cautious surveillance. These data indicate that mutations that can theoretically confer adefovir or tenofovir resistance may emerge in treatment-naive patients.
